MedTrace Logo

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

NCT02340676 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-20

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following allogeneic stem cell transplant.

Conditions

  • Chronic Graft-versus-host-disease

Interventions

PROCEDURE

Extracorporeal Photopheresis (ECP)

Participants receive ECP treatment twice a week for 16 weeks

DRUG

Interleukin-2

Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16

Sponsors & Collaborators

Principal Investigators

  • John Koreth, MBBS,D.Phil · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-08-31
Completion
2025-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02340676 on ClinicalTrials.gov